A Phase I/II Clinical Trial with Randomized, Blinded, Controlled Design to Evaluate the Safety and Immunogenicity of the Recombinant Herpes Zoster Vaccine (CHO Cell) in Healthy Populations Aged 40 Years and Older Post -vaccination
The objective of this study was to evaluate the safety, immunogenicity and immune persistence of recombinant herpes zoster vaccine (CHO cells) with different adjuvant doses in healthy people aged 40 years and older.
100 Clinical Results associated with Yither biotech (Shanghai) Co., Ltd
0 Patents (Medical) associated with Yither biotech (Shanghai) Co., Ltd
100 Deals associated with Yither biotech (Shanghai) Co., Ltd
100 Translational Medicine associated with Yither biotech (Shanghai) Co., Ltd